Completed PHASE1 INTERVENTIONAL 2-arm NCT02740829

Assessment of Intranasal Glucagon on Endogenous Glucose Production

Evaluation of the Effects of Intranasal Glucagon on Endogenous Glucose Production in Humans

Sponsor: University Health Network, Toronto

Conditions Diabetes

Interventions Intranasal glucagon Intranasal placebo

Updated 5 times since 2017 Last updated: Apr 14, 2016 Started: Mar 31, 2015 Primary completion: Jan 31, 2016 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02740829, this PHASE1 trial focuses on Diabetes and remains completed. Sponsored by University Health Network, Toronto, it has been updated 5 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Health Network, Toronto

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.